This seventh issue of Evotec's DDup (Drug Discovery Update) is dedicated to our highly innovative initiatives in the kidney space where Evotec has positioned itself as a key player since the CureNephron initiative with Harvard University initiated in 2012. With NURTuRE and NEPLEX we are building highly productive collaborations between Academia and Pharma once again.

Kidney diseases remain an area of high unmet medical need and an enormous burden to healthcare systems, with more than 600 million patients affected by chronic kidney disease (CKD) globally. Within NURTuRE and NEPLEX we are collaborating with experienced and well-known academic experts and laboratories to lay the foundation for new and more efficient drugs, which are desperately needed to fight this tremendous health threat. To fully explore the potential of our kidney initiatives we created NephTec, a virtual company within Evotec. This enables unrestricted access to our leading drug discovery infrastructures and proprietary pre-clinical databases, in order to accelerate the search for novel targets and pathways together with our partners.

Download the the drug discovery update the learn more about kidney diseases at Evotec.